However, its role in determining sensitivity of ovarian cancer cells to CDDP remains unclear as the literature shows that the presence or absence of p53 can cause resistance, sensitivity or have no effect (Brown et al, 1993; Eliopoulos et al, 1995; Herod et al, 1996; Wu and El-Deiry, 1996; De Freudis et al, 1997; O'Connor et al, 1997; Pestell et al, 1998; 2000). This evidence concerns the gene TP53 and ovarian carcinoma.